Kathy Phillips

Kathy joined Flagship Pioneering in January 2021 and is responsible for providing scientific and strategic insight into Pioneering Medicines' projects and driving the operational efforts of project teams to deliver innovative therapies to patients.
Kathy brings more than 17 years of industry experience leading and managing programs from early pre-clinical stages to NDA submission to this role.
She has been responsible for forming, leading and managing multiple academic collaborations and strategic partnerships both within the US and internationally.
Before joining Flagship, Kathy was at Alkermes where she managed multiple early development programs as well as the Phase 3 Vumerity® program through NDA submission, approval, and transfer to its alliance partner, Biogen.
Prior to Alkermes, Kathy spent seven years at Pfizer in the Inflammation & Immunology Research Unit as a scientist and project leader developing research strategies and providing scientific leadership on early development projects.
Kathy spent several years prior to Pfizer studying the effects of therapies on immune cell populations and tolerance induction at Genzyme and characterizing the cellular immune response to HIV that contributes to protection in AIDS vaccine models.
Kathy earned her B.S.
from Stonehill College and her Master of Liberal Arts (ALM) in Extension Studies, with a concentration in Biology at Harvard University.
Her graduate thesis, under the guidance of Dr. Megan Sykes and Dr. Melanie Ruzek, focused on the mechanism of regulatory T cell induction by anti-thymocyte globulin.